Epigenetic Modifiers for AAV Transgene Expression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods using AAV vectors face challenges in precisely controlling transgene expression, leading to unregulated production and potential toxicity concerns.
Innovation Solution
The use of fusion proteins with targeted zinc finger DNA binding domains and chemical epigenetic modifiers to recruit chromatin modifiers, such as BRD4, to modulate transgene expression by converting chromatin structure between euchromatin and heterochromatin states, allowing for precise regulation of transgene production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are used for gene therapy, then transgene delivery is achieved, but transgene expression cannot be precisely controlled leading to potential toxicity
Solution Approach 1:
The patent applies dynamics by making the transgene expression system adjustable and controllable over time. Chemical epigenetic modifiers enable dynamic regulation of chromatin structure, allowing transgene expression to be turned on or off, or adjusted to different levels, rather than being constitutively active. This resolves the contradiction by providing reliable expression control while minimizing toxicity through precise temporal and quantitative management of transgene product.
Solution Approach 2:
The patent utilizes parameter changes by modifying chromatin structure parameters (euchromatin vs. heterochromatin states) through chemical epigenetic modifiers. These modifiers change the physical and chemical parameters of DNA accessibility, thereby controlling transgene expression levels. This approach enables precise control of expression parameters while avoiding unregulated production that leads to toxicity.
2Productivity
If transgene expression is increased to maximize therapeutic benefit, then therapeutic efficacy improves, but toxicity increases
Solution Approach 1:
The chemical epigenetic modifier system allows dynamic adjustment of transgene expression levels based on therapeutic needs. Expression can be increased to maximize benefit when required, then decreased or halted when therapeutic thresholds are reached, preventing toxicity. This dynamic control resolves the contradiction between productivity and harmful factors.
Solution Approach 2:
The system enables feedback control where transgene expression levels can be monitored and adjusted accordingly through administration of chemical epigenetic modifiers. When transgene product reaches therapeutic levels, modifier administration can be reduced or stopped to prevent excessive accumulation and toxicity, thus resolving the contradiction between maximizing productivity and minimizing harm.
3Manufacturing precision
If chemical epigenetic modifiers are used to modulate transgene expression, then expression precision is improved, but system complexity increases
Solution Approach 1:
Chemical epigenetic modifiers serve as intermediary molecules that bridge the gap between external control and internal chromatin structure. These small molecule mediators interact with chromatin remodeling complexes to induce euchromatin or heterochromatin formation, providing precise expression control without requiring complex genetic circuitry. This resolves the contradiction by achieving manufacturing precision through relatively simple chemical intermediaries rather than complex biological systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise and controlled modulation of transgene expression, enhancing therapeutic benefits while minimizing toxicity by strategically increasing or decreasing transgene production as needed.
Implementation Method 1
a fusion protein comprising a nucleic acid binding domain that binds to the recognition sequence
Implementation Method 2
recruiting epigenetic modifiers to the vector to increase or decrease transgene expression... recruitment of modifiers that generate euchromatin or heterochromatin
Data Source
AI summary
This invention relates to methods and compositions for gene therapy. In particular, the invention relates to methods and compositions for modulating transgene expression from transgene delivery vectors by recruiting epigenetic modifiers to the vector. Using these methods, transgene delivery vectors can be more precisely regulated to produce increased amounts of the transgene product when needed and to decrease expression when needed, thereby providing maximum benefits for gene therapy while minimizing toxicity.